Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis

Research output: Contribution to journalArticlepeer-review


  • Allan Lawrie
  • Helen M Marriott
  • Paul Mercer
  • Simon S Cross
  • Nadine Arnold
  • Vanessa Singleton
  • Alfred A R Thompson
  • Sarah R Walmsley
  • Stephen A Renshaw
  • Ian Sabroe
  • Rachel C Chambers
  • David H Dockrell
  • Moira K B Whyte

Colleges, School and Institutes


The death receptor ligand tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) shows considerable clinical promise as a therapeutic agent. TRAIL induces leukocyte apoptosis, reducing acute inflammatory responses in the lung. It is not known whether TRAIL modifies chronic lung injury or whether TRAIL has a role in human idiopathic pulmonary fibrosis (IPF). We therefore explored the capacity of TRAIL to modify chronic inflammatory lung injury and studied TRAIL expression in patients with IPF.


Original languageEnglish
Pages (from-to)796-803
Number of pages8
Issue number9
Publication statusPublished - 2012